Virtual Workshop featuring presentations & discussions on selected abstracts from the 63rd ASH Annual Meeting

The Post-ASH 2021 iwAL Virtual Workshop will be held on 20-22 January 2022. The program will cover acute lymphoblastic leukemia (ALL) & myelodysplastic syndromes (MDS) on Day 1, and acute myeloid leukemia (AML) on Day 2. Both days will feature a series of short presentations from invited experts on selected abstracts from the 63rd ASH Annual Meeting with interactive panel discussions after each session.

Apply for registration for iwAL here

This event is for hematologists, researchers, nurses, and allied medical professionals only. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that VJHemOnc can communicate with you regarding this event and relevant updates
Scientific Committee:

Prof. Daniel DeAngelo, Boston, USA
Prof. Mark Levis, Baltimore, USA
Prof. Dieter Hoelzer, Frankfurt, Germany
Prof. Richard Stone, Boston, USA
Prof. Bob Löwenberg, Rotterdam, NL
Dr Naval Daver, Houston, USA
Prof. Marion Subklewe, Munich, Germany
Prof. Marina Konopleva, Houston, USA
Prof. Sabina Chiaretti, Rome, Italy
Prof. Andrew Wei, Melbourne, Australia

Agenda (all times EST)
Day 1: Thursday 20th January 2022 – ALL & MDS

ALL Session
Steering Committee: Daniel DeAngelo, Dieter Hoelzer, Sabina Chiaretti, Bijal Shah

9.00 – 9:05 | Welcome Day 1
Dieter Hoelzer/Daniel DeAngelo/Sabina Chiaretti/Bijal Shah

9:05 – 9:45 | Session 1
Chairs: Daniel DeAngelo & Bijal Shah

• Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children’s Oncology Group:  Sumit Gupta– 211

• Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol – a Graall Study: Corentin Orvain – 215

• ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report: Sabina Chiaretti – 216

Discussion – panellists: Sumit Gupta, Corentin Orvain, Sabina Chiaretti

9:45– 10:35 | Session 2
Chairs: Sabina Chiaretti & Dieter Hoelzer

• Ten Year Outcomes of UKALL 2003: A Randomised Clinical Trial of Adjusting Treatment Intensity Based on Minimal Residual Disease: Anthony Moorman – 364

• First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL): Nicola Goekbuget – 362

• A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations): Anjali Advani – 3397

• Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Nicholas Short – 2298

• First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006): Clare Rowntree  – 366

• Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study: Philippe Rousselot – 511

Discussion – panellists: Anthony Moorman, Nicola Goekbuget, Anjali Advani, Nicholas Short, Clare J Rowntree, Philippe Rousselot

10:25 – 11:15 | Session 3
Chairs: Bijal Shah & Daniel DeAngelo

• Treatment-Free Intervals during CD19xCD3 BiTE® Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cell:  Nora Zieger – 513

• Ikaros Mediates Antigen Escape Following CD19 CAR T Cell Therapy in r/r B-ALL: Pablo Domizi – 613

• CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL: Noelle Frey – 469

Discussion – panellists: Nora Zieger, Pablo Domizi, Noelle Frey

ALL-Session wrap up – all Chairs

11:15 – 11:45 | BREAK

MDS Session
Steering Committee: Amer Zeidan, David Sallman

11:55 – 12:35 | Session 4
Chairs: Amer Zeidan, David Sallman, Anne Sophie Kubasch

• Molecular International Prognosis Scoring System for Myelodysplastic Syndromes: Elsa Bernard – 61

• Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group: Marie Sebert – 62

• Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS): The Ideal Phase 2 Study By the GFM Group: Marie Sebert – 63

• Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20–30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954): Mikkael Sekeres – 242

• Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study: Andrew Brunner – 244

Discussion – panellists: Elsa Bernard, Marie Sebert, Mikkael Sekeres, Andrew Brunner

12:35 – 13:25 | Session 5
Chairs: Amer Zeidan, David Sallman, Anne Sophie Kubasch

• Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine: Jacqueline Garcia – 241

• Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome: Amer Zeidan – 537

• A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment‐Naïve High‐Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML): Sangeetha Venugopal – 245

• CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM: Pierre Peterlin – 243

• A Pilot Study of CPX-351 (Vyxeos©) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome:  Rami Komrokji  – 540

• Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML): David Sallman – 246

Discussion – panellists: Amer Zeidan, Rami Komrokji, Sangeetha Venugopal, Jacqueline Garcia, David Sallman, Pierre Peterlin

Apply for registration for iwAL here

Agenda (all times EST)
Day 2: Friday 21st January 2022 – AML

AML Session
Steering Committee: Naval Daver, Marion Subklewe, Andrew Wei

9:00 – 9:50| Session 1: FLT-3
Chairs: Courtney DiNardo, Jessica Altman, Naval Daver, Claudio Cerchione

• Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy: Eunice Wang – 700

• Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia: Pinkal Desai – 32

• Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Jessica Altman – 691

• Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia: Jianxiang Wang – 695

• Outcomes for Patients with Late-Stage Mutant-IDH2 (mIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial: Courtney DiNardo – 1243

• Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor “Triplet” Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML: Musa Yilmaz – 798

Discussion – panellists: Eunice Wang, Jessica Altman, Jianxiang Wang, Musa Yilmaz, Pinkal Desai, Courtney DiNardo

9:50 – 10:35 | Session 2: IDH, MLL and Other Targeted Therapies
Chairs: Mark Levis, Marina Konopleva

• AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation: Pau Montesinos – 697

• Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101): Eytan Stein – 699

• A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia: Andrew Wei – 1261

Discussion – panellists: Mark Levis, Marina Konopleva, Pau Montesinos, Eytan Stein, Andrew Wei

10:35 – 11:30 | Session 3: Novel Frontline Therapies
Chairs: Alexander Perl, Andrew Wei, Richard Stone

• Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML: Naval Daver – 371

• Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Tapan Kadia -367

• Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents: Daniel Pollyea – 224

• Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia: Curtis Lachowiez – 701

• An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia: Andrew Wei  – 368

Discussion – panellists:  Naval Daver, Tapan Kadia, Daniel Pollyea, Curtis Lachowiez, Andrew Wei, Richard Stone

11:30 – 12:15 | Session 4: Immunotherapies
Chairs: Marion Subklewe, Charles Craddock

• Phase 1/1b safety study of Prgn-3006 UltraCAR-T in patients with r/R CD33 AML and higher Risk MDS: David Sallman – 825

• Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia:  Kendra Sweet – 372

• Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN; Andrew Lane – 2346

• Eprenatapopt (APR-246) as combination with maintenance Therapy or TP53 mutated AML or MDS following allogenic SCT- Abstract: Asmita Mishra – 409

Discussion – panellists: Marion Subklewe, Charles Craddock, David Sallman, Kendra Sweet, Andrew Lane, Asmita Mishra

Day 2 Wrap up – Naval Daver, Marion Subklewe, Andrew Wei, Jessica Altman, Charles Craddock, Alexander Perl, Claudio Cerchione, Mark Levis

Apply for registration for iwAL here

This event is for hematologists, researchers, nurses, and allied medical professionals only. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that VJHemOnc can communicate with you regarding this event and relevant updates
The Post-ASH 2021 iwAL Virtual Workshop has been supported by:


Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter